


Azathioprine sodium

Cat. No.:	HY-B0256A
CAS No.:	55774-33-9
Molecular Formula:	C ₉ H ₇ N ₇ NaO ₂ S
Molecular Weight:	300.25
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Azathioprine (BW 57-322) sodium is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis ^{[1][3]} .								
In Vitro	<p>Azathioprine (0-50 μM, 48 hours) sodium can induce severe intracellular GSH depletion with relevant concentrations in both primary rat and human hepatocytes^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>Rat hepatocytes, Human hepatocytes</td> </tr> <tr> <td>Concentration:</td> <td>0-50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24-48 hours</td> </tr> <tr> <td>Result:</td> <td>Shown the decrease in cell viability and intracellular GSH levels in rat hepatocytes as low concentration of 0.5 μM but no significant decrease in cell viability at concentrations below 50 μM as well as GSH depletion was obviously noted at a concentration as low as 1 μM in human hepatocytes.</td> </tr> </table>	Cell Line:	Rat hepatocytes, Human hepatocytes	Concentration:	0-50 μM	Incubation Time:	24-48 hours	Result:	Shown the decrease in cell viability and intracellular GSH levels in rat hepatocytes as low concentration of 0.5 μM but no significant decrease in cell viability at concentrations below 50 μM as well as GSH depletion was obviously noted at a concentration as low as 1 μM in human hepatocytes.
Cell Line:	Rat hepatocytes, Human hepatocytes								
Concentration:	0-50 μM								
Incubation Time:	24-48 hours								
Result:	Shown the decrease in cell viability and intracellular GSH levels in rat hepatocytes as low concentration of 0.5 μM but no significant decrease in cell viability at concentrations below 50 μM as well as GSH depletion was obviously noted at a concentration as low as 1 μM in human hepatocytes.								
In Vivo	<p>Azathioprine (oral gavage, 25-400 mg/kg, everyday, 10days) sodium can affect bone marrow cells, red blood cells, and peripheral blood cytokines and other related parameters in a dose-dependent manner, and can induce apoptosis in female CD-1 mice and ICR mice^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Outbred female CD-1 mice, Female ICR mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>25-400 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; everyday; 10days</td> </tr> <tr> <td>Result:</td> <td>Induced a decrease in erythrocyte-related parameters as well as leukocyte-related parameters in a dose-dependent manner. Induced 52.4%, 35.4%, 17.9%, 16.1% and 15.2% reduction in bone marrow cells at</td> </tr> </table>	Animal Model:	Outbred female CD-1 mice, Female ICR mice ^[3]	Dosage:	25-400 mg/kg	Administration:	Oral gavage; everyday; 10days	Result:	Induced a decrease in erythrocyte-related parameters as well as leukocyte-related parameters in a dose-dependent manner. Induced 52.4%, 35.4%, 17.9%, 16.1% and 15.2% reduction in bone marrow cells at
Animal Model:	Outbred female CD-1 mice, Female ICR mice ^[3]								
Dosage:	25-400 mg/kg								
Administration:	Oral gavage; everyday; 10days								
Result:	Induced a decrease in erythrocyte-related parameters as well as leukocyte-related parameters in a dose-dependent manner. Induced 52.4%, 35.4%, 17.9%, 16.1% and 15.2% reduction in bone marrow cells at								

concentrations of 40, 60, 80, 100 and 120 mg/kg, respectively while fms-like tyrosine kinase-3 (FLT-3) ligand (FL)-related cytokines were increased.
Increased induction of apoptosis.

CUSTOMER VALIDATION

- APL Bioeng. 2023 Aug 11;7(3):036108.
- Comput Struct Biotec. 2023 Feb 24.
- Biotechnol Bioeng. 2021 Sep 3.
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. SoniaChavez-Alvarez, et al. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020 Nov-Dec;95(6):731-736.
- [2]. Yue-Ting Wu, et al. Azathioprine hepatotoxicity and the protective effect of liquorice and glycyrrhizic acid. Phytother Res. 2006 Aug;20(8):640-5. doi: 10.1002/ptr.1920.
- [3]. Gemma Molyneux, et al. The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse. Int J Exp Pathol. 2008 Apr;89(2):138-58.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA